A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia

Ann Hematol. 2009 Jan;88(1):85-8. doi: 10.1007/s00277-008-0541-5. Epub 2008 Jul 25.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal* / administration & dosage
  • Antibodies, Monoclonal* / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Female
  • Humans
  • Immunophenotyping
  • In Situ Hybridization, Fluorescence
  • Leukemia, Prolymphocytic, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Mitoxantrone* / administration & dosage
  • Mitoxantrone* / therapeutic use
  • Remission Induction
  • Rituximab
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Mitoxantrone
  • Vidarabine
  • fludarabine